US/UK/Canada

Share

Contacts

  • Elos Medtech AB (publ)
    Torsgatan 5B, 411 04 Göteborg
    +46 10 - 171 20 00
    http://www.elosmedtech.com

    • Quotes

    “We will continue to collaborate with our present customers, but also increase our collaboration with technical partners”
    Soren Olesen, Dental Business Director, Elos Medtech
    “Keeping a close dialogue with our partners and maintaining a high level of competence has led to a product portfolio with the right focus – simple and innovative dental products for an open digital workflow.”
    Soren Olesen, Dental Business Director, Elos Medtech
    Elos Medtech is excited to highlight orthopaedics as one of the primary areas of focus and to execute on our market specific strategies. This is a natural step toward achieving our growth targets and capitalizing on our 2015 acquisition of Onyx Medical
    Jan Wahlström, CEO and President.
    Pick a time period -
    Tags ( Active)

    Global Medtech Leader Elos Medtech Celebrates 100 Years of Innovation and Partnership

    Elos Medtech, a global provider of medical technology solutions, proudly announces a momentous achievement as it reaches the remarkable milestone of 100 years this June. Founded in June 1923 as a Swedish manufacturing enterprise that specialized in repairing forestry equipment, the company management soon realized the enormous potential of leveraging their precision engineering skills in an emerging medical technology market. The company embarked on a journey partnering with healthcare professionals, research institutions and industry experts worldwide. A collaboration with Professor

    Elos Medtech - Year-end Report, 1 January - 31 December, 2022

    October – December 2022 · Net sales for the fourth quarter amounted to SEK 229.5 (184.2) million, an increase of 24.6 percent compared to the same quarter last year. Net sales in local currencies increased by 13.8 percent. · Operating profit amounted to SEK 17.6 (25.3) million, corresponding to an operating margin of 7.7 (13.7) percent. · Profit after net financial items amounted to SEK 1.4 (24.8) million. Net financial items were negatively affected by exchange rates of SEK -8.3 (1.2) million and totaled SEK -16.3 (-0.5) million. · Profit after tax amounted to SEK 0.4 (19.5)

    Elos Medtech - Year-end Report, 1 January - 31 December, 2021

    October - December 2021 · Net sales for the fourth quarter amounted to SEK 184.2 (154.8) million, an increase of 19.0 percent compared to the same quarter last year. Net sales in local currencies increased by 17.7 percent. · Operating profit was SEK 25.3 (18.9) million, corresponding to an operating margin of 13.7 (12.2) percent. · Profit after financial items amounted to SEK 24.8 (13.3) million. Net financial items were positively affected by exchange rate differences of SEK 1.2 (-3.5) million and totaled SEK -0.5 (-5.6) million. · Profit after tax amounted to SEK 19.5 (11.1)

    Elos Medtech - Year-end report, 1 January - 31 December, 2020

    STRONG CONCLUSION TO THE YEAR October - December · Net sales for the fourth quarter amounted to SEK 154.8 (158.3) million, a decrease of 2.2 percent compared to the same quarter last year. Net sales in local currencies increased by 2.7 percent. · Operating profit was SEK 18.9 (14.1) million, corresponding to an operating margin of 12.2 (8.9) percent. · Operating profit has been positively affected by SEK 1.0 million with respect to government support received owing to Covid-19. · Earnings after financial items amounted to SEK 13.3 (10.0) million. Net financial items were

    Elos Medtech signs global distribution agreement with Nobel Biocare

    Elos Medtech signs a global distribution agreement of selected products with Nobel Biocare. Elos Medtech and Nobel Biocare have been business partners over 25 years, mainly within contract-manufacturing, and are now expanding the collaboration within the growing market of digital dentistry. By this global distribution agreement, Nobel Biocare’s prosthetic product portfolio is extended with a private labelled product from the Elos Accurate[®] product family. The agreement also includes Elos Accurate[ ]Analog for Printed Models as third-party product, compatible with multiple dental

    Strong Demand for Life Science – Elos Medtech Expanding in Sweden

    Elos Medtech has, owing to a growing number of orders, decided to increase production capacity by expanding Elos Medtech´s site in Skara. Over the last few years, Elos Medtech has experienced increased demand from new and established customers for advanced, injection-molded polymer products. The company’s customers are global and operate primarily within the growing diagnostics market. The strong demand is due to the fact that customers are looking to outsource large parts of their production lines or production in its entirety. Elos Medtech’s focus on injection molding in polymer

    Elos Medtech has been granted patent for a new dental drill concept

    Elos Medtech announces that the company has been granted approval and registration of a patent for a dental drill system by the US Patent and Trademark Office and European Patent Office. The patent includes a drill system used for implant surgery and consists of a drill, a guide sleeve which guides the drill during surgery and a drill stop. Surgery of dental implants involves many steps and procedures. During surgery it is essential that the drilling is as accurate as possible to reduce the impact of soft tissue and jawbone as well as reduce the risk of complications. Elos Medtech’s

    Elos Medtech Interim Report January 1 - June 30, 2019

    ROBUST GROWTH AND AN IMPROVED OPERATING MARGIN April - June 2019 • Net sales for the second quarter increased to SEK 184.1 (166.0) million, which corresponds to organic growth of 10.9 percent. After currency conversions, our growth rate was 7.1 percent.• Operating profit amounted to SEK 15.6 (5.2) million. Operating margin for the second quarter of 2019 was 8.5 percent, up from 3.1 percent in the same period in 2018.• Profit after net financial items was SEK 8.6 (5.2) million. Net financial items were negatively affected by a net exchange rate loss of SEK -3.9 (2.4) million and

    Elos Medtech – Annual Report 2018 published

    The Swedish version of Elos Medtech Annual Report 2018 have today been published on our web site www.elosmedtech.com The English version of Elos Medtech Annual Report 2018 will be available at the web site www.elosmedtech.com in late April. Göteborg, April 2, 2019 Elos Medtech AB (publ) For further information, please contact: Jan Wahlström, CEO, +46 70 212 18 89, jan.wahlstrom@elosmedtech.com  or Christian Bergaust CFO, +46 70 293 50 40, christian.bergaust@elosmedtech.com For additional information about the Elos Medtech Group, visit www.elosmedtech.com This information

    Elos Medtech appoints Operational Excellence Director

    Elos Medtech appoints Conny Jakobsson, Managing Director of Elos Medtech Tianjin in China, to Operational Excellence Director for Elos Medtech. At Elos Medtech we remain committed to growth and the positive transformation of our business. One of our strategic focus areas ’Operational Excellence and Continuous Improvements’ will support our growth and profitability targets by systematically developing our operations, ensuring increased capacity and improving the competitiveness of our offerings to customer partners. We are now strengthening this area by appointing Conny Jakobsson as

    Elos Medtech - Year-end report, January 1 – December 31, 2018

    Double digit growth and improved profitability • Net sales for the year increased and amounted to SEK 644.7 million (577.9), corresponding to organic growth of 11.6%. After currency adjustments, growth was 8.0%.• Operating profit before non-recurring items amounted to SEK 47.6 million (42.7). Operating margin before non-recurring items for 2018 was 7.4%, compared to 7.4% the previous year.• Operating profit after non-recurring items amounted to SEK 38.9 million (42.7). Operating margin after non-recurring items for 2018 was 6.0%, compared to 7.4% the previous year.• Profit after

    Elos Medtech Interim report, 1 January - 31 March , 2017

    The global market for medical technology products is growing in a number ofour business areas and we see favourable growth opportunities.•   Net sales amounted to SEK 140.9 M (140.4), corresponding to organic growth of 0.4%. · Operating profit totalled SEK 13.3 M (12.0).  · Profit after net financial items amounted to SEK 9.6 M (6.8). Net financial items were negatively impacted by exchange-rate differences of SEK 1.4 M (neg: 1.7). · Profit after tax amounted to SEK 7.2 M (4.9), corresponding to SEK 1.19 (0.80) per share. · Cash flow was SEK 11.9 M (20.5) from

    Elos Medtech – Annual Report 2016 published

    The Swedish version of Elos Medtech Annual Report 2016 was today published at our web site www.elosmedtech.com The printed version will be distributed end of week 15 to shareholders who wish to receive corporate information in accordance with Euroclear. The report can also be ordered at info@elosmedtech.com The English version of Elos Medtech Annual Report 2016 will be available at the web site www.elosmedtech.com in late April. Göteborg, April 5, 2017 Elos Medtech AB (publ) For further information, please contact: Jan Wahlström, CEO, +46 70 212 18 89, jan.wahlstrom@

    The Nomination Committee´s proposal for new Chairman and new Board Member.

    As Stig-Arne Blom has announced that he will not stand for re-election as Board Member and Chairman of Elos Medtech AB the Nomination Committee will propose to the Annual General Meeting to appoint Yvonne Mårtensson as new Chairman. Yvonne Mårtensson has been a Board Member of Elos Medtech since 2015. In addition to Elos Medtech she also holds Board Member positions in Arcoma, Synthetic MR and SwedenBIO. Furthermore, the Nomination Committee will propose Jon Risfelt to be appointed as new Board Member. Jon Risfelt is Chairman or Board Member of several public and private companies,

    Elos Medtech - Year-end report, 1 January - 31 December 2016

    10% growth and improved profit• Net sales increased to SEK 552.0 M (503.7) which, adjusted for exchange-rate fluctuations,corresponds to a rise of 10.1%, of which organic growth was 0.3%. • Operating profit improved to SEK 42.7 M (30.5). • Profit after net financial items totalled SEK 37.9 M (22.5). Net financial items were positively affected by exchange-rate differences of SEK 5.4 M (neg: 0.4). • Profit after tax amounted to SEK 26.4 M (16.1), corresponding to SEK 4.37 (2.66) per share. • Cash flow from operating activities improved to SEK 98.3 M (61.6). Cash flow after

    Elos Medtech moves the head quarter to Gothenburg

    Elos Medtech Group will move the head quarter from Lidköping to Gothenburg on November 1st 2016. The relocation of the head quarter to Gothenburg is a part of concentrating and gathering more of our central resources to one location. Gothenburg is a centre in medical technology, where we have gradually built up a sales organization during the past year. Now we also gather the central finance function to Gothenburg. A number of people in sales and marketing have already been located in Gothenburg. New address is: Elos Medtech ABNellickevägen 22 412 63 Göteborg, Sweden

    Elos Medtech – subscription of warrants

    The management and key employees within the Elos Medtech Group has signed a total of 251,500 warrants in the incentive program 2016/2019 that the Annual General Meeting decided on in April, 2016. At the Annual General Meeting of Elos Medtech AB, April 26 2016, it was decided to implement an incentive program whereby a maximum of 318,473 warrants can be transferred to senior executives and key employees within the Elos Medtech Group. A total of 251,500 warrants were subscribed, of which 63,000 warrants were signed by CEO Jan Wahlström. In accordance with the AGM's decision, the

    Elos Medtech - Interim report, 1 January – 30 September 2016

    Continued improved earnings and strong cash flow• Net sales increased to SEK 418.7 M (367.7) which, adjusted for exchange-rate fluctuations, corresponds to a rise of 14.7%, of which organic growth was 2.1%. • Operating profit improved to SEK 39.7 M (25.5, adjusted for non-recurring items of 34.0). • Profit after net financial items totalled SEK 32.1 M (20.0). Net financial items were positively affected by exchange-rate differences of SEK 1.1 M (0.1).  • Profit after tax amounted to SEK 23.5 M (12.9), corresponding to SEK 3.88 (2.13) per share. • Cash flow from operating

    Elos Medtech Nomination Committee appointed ahead of Annual General Meeting 2017

    In accordance with resolutions passed at the Annual General Meeting in 2016, the Elos Medtech Nomination Committee shall comprise no fewer than four and no more than six members, of whom one is to be the Chairman of the Board. The members are to be appointed by those shareholders who, at the end of the month of August, are the largest shareholders in terms of voting rights in the company, as well as by the party who addition to the aforementioned is the largest shareholder. When appointing the Nomination Committee, the rules of the Swedish Code of Corporate Governance (the Code) are to

    Elos Medtech Interim report, 1 January – 30 June 2016

    Sales growth and improved operating profit• Net sales for the first half of the year increased to SEK 292.0 M (244.6), which adjusted for exchange-rate fluctuations corresponds to an increase of 20.2%, of which organic growth was 1.1%. • Operating profit totalled SEK 28.0 M (19.4, adjusted for non-recurring items of 26.4). • Profit after net financial items totalled SEK 21.3 M (16.7). Net financial items were negatively impacted by exchange-rate differences of SEK 0.2 M (pos: 0.3).  • Profit after tax amounted to SEK 15.1 M (11.3), corresponding to SEK 2.49 (1.87) per share. •

    Elos Medtech AB (publ) – Annual General Meeting 2016

    The Annual General Meeting (AGM) resolved -  Dividend for fiscal year 2015 of SEK 1.00 per share -  The issue of warrants -  Anders Birgersson as new member of the BoardAt the AGM of Elos Medtech AB on April 26 2016, the Board’s proposal of a dividend for fiscal year 2015 of SEK 1.00 per share dividend was approved. President Johannes Lind-Widestam provided information about the business trend during 2015 and presented the interim report for the first quarter of 2016. The AGM resolved that the compensation payable to the Board of Directors shall be divided as follows: SEK 330,

    Elos Medtech Interim report, 1 January-31 March 2016

    • Net sales amounted to SEK 140.4 M (105.5), which adjusted for exchange-rate fluctuations corresponds to an increase of 34.5%, of which organic growth was negative 2.0%. • Operating profit totalled SEK 12.0 M (10.2 before non-recurring items of 4.5). • Profit after net financial items totalled SEK 6.8 M (7.6). Net financial items were negatively impacted by exchange-rate differences of SEK negative1.7 M (2.9). • Profit after tax amounted to SEK 4.9 M (5.6), corresponding to SEK 0.80 (0.93) per share. • Cash flow from operating activities was SEK 20.5 M (12.1) and, after

    Elos Medtech – Annual Report 2015 published

    The Swedish version of Elos Medtech Annual Report 2015 was today published at our web site www.elosmedtech.com The printed version will be distributed end of week 14 to shareholders who wish to receive corporate information in accordance with Euroclear. The report can also be ordered at info@elosmedtech.com The English version of Elos Medtech Annual Report 2015 will be available at the web site www.elosmedtech.com in late April. Lidköping, March 31, 2016 Elos Medtech AB (publ)

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media

    Twitter